Search research articles
Contact Us
Filters
Showing results (221-230 of 323) with videos related to
Page
of 33
Sort By:
British Journal of Cancer
|
June 6, 2022
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Roberto Moretto, Andrew Elliott, Daniele Rossini, et al.
Future Oncology (London, England)
|
June 12, 2025
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma
Simone Oldani, Natalie Prinzi, Federica Morano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2023
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taieb, et al.
Nature Medicine
|
August 1, 2022
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 23, 2018
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase
Sarit Schwartz, Chris Szeto, Yuan Tian, et al.
The Oncologist
|
May 6, 2020
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
Filippo Pietrantonio, Fotios Loupakis, Giovanni Randon, et al.
Journal for Immunotherapy of Cancer
|
April 14, 2021
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Giovanni Fucà, Francesca Corti, Margherita Ambrosini, et al.
British Journal of Cancer
|
May 20, 2020
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
Giovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 30, 2025
FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study
Chiara Pircher, Federico Nichetti, Mario Domenico Rizzato, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 7, 2023
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study
Elisabeth S Bergen, Lorenzo Pilla, Edouard Auclin, et al.
Page
of 33
Search research articles
Search
Showing results (221-230 of 323) with videos related to
Sort By:
Page
of 33
British Journal of Cancer
|
June 6, 2022
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Roberto Moretto, Andrew Elliott, Daniele Rossini, et al.
Future Oncology (London, England)
|
June 12, 2025
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma
Simone Oldani, Natalie Prinzi, Federica Morano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2023
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taieb, et al.
Nature Medicine
|
August 1, 2022
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 23, 2018
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase
Sarit Schwartz, Chris Szeto, Yuan Tian, et al.
The Oncologist
|
May 6, 2020
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
Filippo Pietrantonio, Fotios Loupakis, Giovanni Randon, et al.
Journal for Immunotherapy of Cancer
|
April 14, 2021
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Giovanni Fucà, Francesca Corti, Margherita Ambrosini, et al.
British Journal of Cancer
|
May 20, 2020
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
Giovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
December 30, 2025
FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study
Chiara Pircher, Federico Nichetti, Mario Domenico Rizzato, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 7, 2023
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study
Elisabeth S Bergen, Lorenzo Pilla, Edouard Auclin, et al.
Page
of 33